# A click-activated MMAE prodrug switched on by an injected biopolymer or by a HER2-binding antibody fragment

Source: https://onco.cc/key-papers/paper-mcfarland-auristatin-protodrug-click-activation-acs-cent-sci-2023/  
OnCo record `paper-mcfarland-auristatin-protodrug-click-activation-acs-cent-sci-2023` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A mouse study showing the same chemistry can be steered by a tumour-seeking protein instead of an injection, and can switch on MMAE, a toxin too harsh to give on its own.

## Summary

Shasqi extends its platform in two directions. The drug is monomethyl auristatin E (MMAE), modified with a trans-cyclooctene to form the prodrug SQP22, which reduced its cytotoxicity in cells and in animals. The activator is either the tetrazine-modified hyaluronate SQL70 injected into the tumour, or SQT01, a tetrazine-modified HER2-targeting antigen-binding fragment given by infusion.

SQP22 with SQL70 had anti-tumour effects in the Karpas 299 and RENCA mouse models and showed that the click reaction was required for activation. SQP22 with SQT01 had anti-tumour effects in the HER2-positive NCI-N87 xenograft, showing that activation at the tumour could be achieved with both components given systemically. Toxicity was limited to transient myelosuppression and moderate loss of body weight.

## Fields

- Kind: Key paper
- Last checked: 2026-11-16
- Also known as: Click Chemistry Selectively Activates an Auristatin Protodrug with either Intratumoral or Systemic Tumor-Targeting Agents
- Journal: ACS Central Science
- Year: 2023
- DOI: 10.1021/acscentsci.3c00365
- Authors: McFarland JM, Alečković M, Coricor G, et al.
- Findings: Capping MMAE with a trans-cyclooctene (SQP22) reduced its cytotoxicity in vitro and in vivo.; SQP22 with intratumoral SQL70 showed anti-tumour effects in Karpas 299 and RENCA models.; SQP22 with the systemically given HER2-binding fragment SQT01 showed anti-tumour effects in the HER2-positive NCI-N87 xenograft.
- What it means: It is the published basis for the antigen-targeted programmes on Shasqi's pipeline, which no longer need a tumour that can be injected. None of these has been tested in people.
- Caveats: Mouse models only; the abstract gives no effect sizes.; Funded and authored by Shasqi.

## Sources

- ACS Cent Sci 2023: https://doi.org/10.1021/acscentsci.3c00365
- PubMed: https://pubmed.ncbi.nlm.nih.gov/37521794/
- Europe PMC (free full text): https://europepmc.org/article/MED/37521794

## Connected records

- technologies: [Click-activated prodrugs (bioorthogonal drug activation in the body)](https://onco.cc/technologies/click-activated-prodrugs/)
- targets: [HER2](https://onco.cc/targets/her2/)
- companies: [Shasqi](https://onco.cc/companies/shasqi/)
- terms: [MMAE](https://onco.cc/terms/mmae/)

---
JSON: https://onco.cc/api/v1/entities/paper-mcfarland-auristatin-protodrug-click-activation-acs-cent-sci-2023.json